secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protagenic Therapeutics, Inc.new (PTIX)
CIK:        0001022899
Form:       8-K
Filed at:   2025-05-19T23:59:59+00:00
Accession:  0001641172-25-011387
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.90
Item codes: 1.01, 5.03, 2.01, 3.02, 3.03, 5.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud

Protagenic Therapeutics acquires Phytanix Bio in share exchange, appoints new CEO and directors
--------------------------------------------------------------------------------

- Acquired 100% of Phytanix Bio common shares from Alterola Biotech and EMC2 Capital as of May 15, 2025
- Issued 117,690 common shares, 5,705 Series C Preferred, 950,000 Series C-1 Preferred, and 20,000 Series D Preferred to Phytanix stockholders
- Appointed Barrett Evans as President and CEO, Colin Stott as COO and director, and Jennifer Chao as director; Andrew Slee promoted to Chief Development Officer
- Resignations of directors Khalil Barrage, Tim Wright, and Robert Stein effective immediately before closing
- Filed certificates of designation for Series C and C-1 Non-Voting Convertible Preferred Stock on May 15, 2025

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1022899/000164117225011387/0001641172-25-011387-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1022899/000164117225011387/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-011387

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer